AS A CRITICAL CARE PHARMACIST, You can help guide empiric use of systemic antifungals in adults. There are over a dozen risk factors for invasive candidiasis. But studies in patients withOUT neutropenia haven’t pinned down the best approach for empiric antifungal use.
PATIENT SELECTION. Think about adding an empiric antifungal to antibiotics for intra-abdominal infections in certain patients LIKE those with recent abdominal surgery, anastomotic leak, or necrotizing pancreatitis.
Also consider starting an antifungal in an ICU patient with persistent fever despite broad-spectrum antibiotics AND who has fungal risk factors, such as parenteral nutrition, dialysis, or severe burns. Rely on clinical judgment to guide decisions, it’s too soon to say which risks are most important or if having more than one is key. For example, consider an antifungal for a critically ill patient with sepsis, ongoing fever despite a few days of vancomycin and meropenem and receiving parenteral nutrition.
ANTIFUNGAL CHOICE. Use an echinocandin (anidulafungin [Ecalta], micafungin [Mycamine], caspofungin [Cancidas], etc) if a patient has hemodynamic instability, recent azole exposure or colonization with fluconazole-resistant Candida. But consider fluconazole in a patient withOUT these risks AND if local data show Candida albicans is generally fluconazole-susceptible. Save amphotericin-B as last-line due to adverse effects.
DURATION. Usually continue an empiric antifungal for 2 weeks if patients respond (afebrile, etc), since invasive candidiasis without positive cultures is common. But stop empiric antifungals after 4 to 5 days if there’s no improvement and no other evidence of invasive candidiasis. Or if available, consider a beta-D-glucan test, negative results can help rule out fungal infection. But don’t rely on it to rule in infection as false positives are common.
REFERENCES
-
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. Available at: https://academic.oup.com/cid/article/62/4/e1/2462830
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Møller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. Available at: https://journals.lww.com/ccmjournal/Fulltext/2021/11000/Surviving_Sepsis_Campaign__International.21.aspx
Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, Garnacho-Montero J, Kanj SS, Machado FR, Montravers P, Sakr Y, Sanguinetti M, Timsit JF, Bassetti M. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019 Jun;45(6):789-805. Available at: https://link.springer.com/article/10.1007%2Fs00134-019-05599-w
Thomas-Rüddel D, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-Analysis. Chest. 2021 Oct 18:S0012-3692(21)04112-X. Available at: https://www.sciencedirect.com/science/article/pii/S001236922104112X